Evidence map›Paper›PMID 35325076›Full record

SynthesisJournal of Crohn's & colitis2022

Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease.

Nik Sheng Ding, Daniel Tassone, Ibrahim Al Bakir, Kyle Wu, Alexander J Thompson, William R Connell, George Malietzis, Phillip Lung, Siddharth Singh, Chang-Ho Ryan Choi and 3 more

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Journal of Crohn's & colitis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Nik Sheng DingInflammatory Bowel Disease Unit, St Mark's Hospital, Harrow, UK.ORCID 0000-0002-6232-1948
Daniel TassoneGastroenterology Department, St Vincent's Hospital, Melbourne, Australia.ORCID 0000-0002-1882-8135
Ibrahim Al BakirInflammatory Bowel Disease Unit, St Mark's Hospital, Harrow, UK.
Kyle WuGastroenterology Department, St Vincent's Hospital, Melbourne, Australia.
Alexander J ThompsonGastroenterology Department, St Vincent's Hospital, Melbourne, Australia.
William R ConnellGastroenterology Department, St Vincent's Hospital, Melbourne, Australia.
George MalietzisDepartment of Surgery and Cancer, Imperial College, London, UK.
Phillip LungInflammatory Bowel Disease Unit, St Mark's Hospital, Harrow, UK.
Siddharth SinghDivision of Gastroenterology and Division of Biomedical Informatics, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-2640-7269
Chang-Ho Ryan ChoiInflammatory Bowel Disease Unit, St Mark's Hospital, Harrow, UK.
Simon GabeInflammatory Bowel Disease Unit, St Mark's Hospital, Harrow, UK.
John T JenkinsDepartment of Surgery and Cancer, Imperial College, London, UK.
Ailsa HartInflammatory Bowel Disease Unit, St Mark's Hospital, Harrow, UK.
St Mark's Hospital · GBSt Vincent's Hospital Melbourne · AUImperial College London · GBUniversity of California San Diego · US

Funding

San Diego Biomedical Informatics Education & Research (SABER)T15LM011271 · NLM · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHAMIM NEMATI · 2012 to 2026
$9.7M
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
Predicting Short- and Long-term Risk of Serious Infections in Older Patients with Inflammatory Bowel DiseasesR03DK129631 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2021 to 2022
$203k
NIDDK NIH HHS K23 DK117058NIDDK NIH HHS R03 DK129631NIH HHS K23DK117058NLM NIH HHS T15 LM011271NLM NIH HHS T15LM011271
6 · The paper itself

Abstract

BACKGROUND AND

aimsAlterations in body composition are common in inflammatory bowel disease [IBD] and have been associated with differences in patient outcomes. We sought to consolidate knowledge on the impact and importance of body composition in IBD.

methodsWe performed a systematic search of MEDLINE, EMBASE and conference proceedings by combining two key research themes: inflammatory bowel disease and body composition.

resultsFifty-five studies were included in this review. Thirty-one focused on the impact of IBD on body composition with a total of 2279 patients with a mean age 38.4 years. Of these, 1071 [47%] were male. In total, 1470 [64.5%] patients had Crohn's disease and 809 [35.5%] had ulcerative colitis. Notably, fat mass and fat-free mass were reduced, and higher rates of sarcopaenia were observed in those with active IBD compared with those in clinical remission and healthy controls. Twenty-four additional studies focused on the impact of derangements in body composition on IBD outcomes. Alterations in body composition in IBD are associated with poorer prognoses including higher rates of surgical intervention, post-operative complications and reduced muscle strength. In addition, higher rates of early treatment failure and primary non-response are seen in patients with myopaenia.

conclusionsPatients with IBD have alterations in body composition parameters in active disease and clinical remission. The impacts of body composition on disease outcome and therapy are broad and require further investigation. The augmentation of body composition parameters in the clinical setting has the potential to improve IBD outcomes in the future.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesAdultBody CompositionChronic DiseaseFemaleHumansMaleBody compositionfat massinflammatory bowel diseasemuscle mass

Identifiers

PMID35325076
PMCPMC9455788
OpenAlexW4221004918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.